Sera Prognostics, Inc.
Sera Prognostics, Inc. (Nasdaq: SERA) is a women’s health company that develops and commercializes blood-based biomarker tests and predictive analytics focused on pregnancy outcomes. Its commercial product, the PreTRM test, is a non-invasive blood test administered during weeks 18 through 20 of a singleton pregnancy… From the company’s description.
Over the twelve months to Sep 30, 2026, Sera Prognostics, Inc. reported revenue of $0.10M, up 1.1% from a year earlier, and a net loss of $33.47M. Operations used $28.50M in cash. In fiscal 2025, it reported revenue of $0.08M, up 5.2% from fiscal 2024, and a net loss of $31.93M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Sera Prognostics, Inc. does
In the company’s own words
Sera Prognostics, Inc. (Nasdaq: SERA) is a women’s health company that develops and commercializes blood-based biomarker tests and predictive analytics focused on pregnancy outcomes. Its commercial product, the PreTRM test, is a non-invasive blood test administered during weeks 18 through 20 of a singleton pregnancy to predict the risk of spontaneous preterm birth before 37 weeks. The company’s customers and intended users include pregnant women, physicians and other health care providers, insurers, pharmaceutical companies, researchers and related businesses. Sera’s proprietary platform combines pregnancy specimen biobanks, proteomics, mass spectrometry, immunoassays and bioinformatics to discover and validate predictors of pregnancy complications. It is also developing tests and analytical products for conditions including preeclampsia and gestational diabetes. Sera conducts clinical studies and health economic analyses to support the use of its tests and works with health care systems, physician networks, employers and insurance payers on payment and access. Its trademarks include PreTRM, PreTRM Global and LikeMine.
Company details
- Sector
- Health Care
- Industry (SIC)
- Health Services
- Headquarters
- SALT LAKE CITY, UT
- Fiscal year end
- December
- CIK
- 1534969
- SIC
- 8071
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Sera Prognostics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Sera Prognostics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Sera Prognostics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Sera Prognostics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Sera Prognostics, Inc.'s last four quarterly filings that the numbers alone won't show?”